Cargando…
Raltegravir for HIV-1 infected children and adolescents: efficacy, safety, and pharmacokinetics
Raltegravir was the first HIV integrase strand-transfer inhibitor to be approved by the US FDA, in October 2007, for the treatment of HIV-1 infection in combination with other antiretroviral agents. Raltegravir can be used in treatment-naïve and -experienced patients, as well as for the treatment of...
Autores principales: | , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove Medical Press
2013
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3912854/ https://www.ncbi.nlm.nih.gov/pubmed/24600298 http://dx.doi.org/10.2147/AHMT.S29462 |
_version_ | 1782302146390130688 |
---|---|
author | Larson, Kajal B King, Jennifer R Acosta, Edward P |
author_facet | Larson, Kajal B King, Jennifer R Acosta, Edward P |
author_sort | Larson, Kajal B |
collection | PubMed |
description | Raltegravir was the first HIV integrase strand-transfer inhibitor to be approved by the US FDA, in October 2007, for the treatment of HIV-1 infection in combination with other antiretroviral agents. Raltegravir can be used in treatment-naïve and -experienced patients, as well as for the treatment of multidrug-resistant infection. Raltegravir exists in two formulations: a film-coated tablet administered orally at 400 mg twice daily, and a chewable tablet administered orally at 300 mg twice daily. In 2011, raltegravir was also approved for the treatment of children and adolescents, ages 2–18 years. For adolescents (ages 12–18 years), the recommended dose is 400 mg twice daily (film-coated tablet). If children (ages 6–12 years) weigh at least 25 kg, the film-coated tablet is recommended at 400 mg twice daily. Otherwise, patients receive the chewable tablet according to weight-based dosing at approximately 6 mg/kg/dose. Studies are ongoing for children ages 4 weeks to 2 years, and preliminary efficacy and safety data are promising. This article reviews current studies on the efficacy, safety, and pharmacokinetics of raltegravir in the pediatric population and the challenges of treating HIV in children and adolescents. |
format | Online Article Text |
id | pubmed-3912854 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2013 |
publisher | Dove Medical Press |
record_format | MEDLINE/PubMed |
spelling | pubmed-39128542014-03-05 Raltegravir for HIV-1 infected children and adolescents: efficacy, safety, and pharmacokinetics Larson, Kajal B King, Jennifer R Acosta, Edward P Adolesc Health Med Ther Review Raltegravir was the first HIV integrase strand-transfer inhibitor to be approved by the US FDA, in October 2007, for the treatment of HIV-1 infection in combination with other antiretroviral agents. Raltegravir can be used in treatment-naïve and -experienced patients, as well as for the treatment of multidrug-resistant infection. Raltegravir exists in two formulations: a film-coated tablet administered orally at 400 mg twice daily, and a chewable tablet administered orally at 300 mg twice daily. In 2011, raltegravir was also approved for the treatment of children and adolescents, ages 2–18 years. For adolescents (ages 12–18 years), the recommended dose is 400 mg twice daily (film-coated tablet). If children (ages 6–12 years) weigh at least 25 kg, the film-coated tablet is recommended at 400 mg twice daily. Otherwise, patients receive the chewable tablet according to weight-based dosing at approximately 6 mg/kg/dose. Studies are ongoing for children ages 4 weeks to 2 years, and preliminary efficacy and safety data are promising. This article reviews current studies on the efficacy, safety, and pharmacokinetics of raltegravir in the pediatric population and the challenges of treating HIV in children and adolescents. Dove Medical Press 2013-08-27 /pmc/articles/PMC3912854/ /pubmed/24600298 http://dx.doi.org/10.2147/AHMT.S29462 Text en © 2013 Larson et al. This work is published by Dove Medical Press Ltd, and licensed under Creative Commons Attribution – Non Commercial (unported, v3.0) License The full terms of the License are available at http://creativecommons.org/licenses/by-nc/3.0/. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Ltd, provided the work is properly attributed. |
spellingShingle | Review Larson, Kajal B King, Jennifer R Acosta, Edward P Raltegravir for HIV-1 infected children and adolescents: efficacy, safety, and pharmacokinetics |
title | Raltegravir for HIV-1 infected children and adolescents: efficacy, safety, and pharmacokinetics |
title_full | Raltegravir for HIV-1 infected children and adolescents: efficacy, safety, and pharmacokinetics |
title_fullStr | Raltegravir for HIV-1 infected children and adolescents: efficacy, safety, and pharmacokinetics |
title_full_unstemmed | Raltegravir for HIV-1 infected children and adolescents: efficacy, safety, and pharmacokinetics |
title_short | Raltegravir for HIV-1 infected children and adolescents: efficacy, safety, and pharmacokinetics |
title_sort | raltegravir for hiv-1 infected children and adolescents: efficacy, safety, and pharmacokinetics |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3912854/ https://www.ncbi.nlm.nih.gov/pubmed/24600298 http://dx.doi.org/10.2147/AHMT.S29462 |
work_keys_str_mv | AT larsonkajalb raltegravirforhiv1infectedchildrenandadolescentsefficacysafetyandpharmacokinetics AT kingjenniferr raltegravirforhiv1infectedchildrenandadolescentsefficacysafetyandpharmacokinetics AT acostaedwardp raltegravirforhiv1infectedchildrenandadolescentsefficacysafetyandpharmacokinetics |